证券代码：600673 证券简称：东阳光 编号：临 2024-79 号 广东东阳光科技控股股份有限公司 关于控股股东之一致行动人部分股份解质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广东东阳光科技控股股份有限公司（以下简称"公司"）于近日收到控股股 东之一致行动人乳源阳之光的通知，获悉其将其持有的公司部分无限售流通股进 行了解质押，具体事项如下： | 股东名称 | 乳源阳之光铝业发展有限公司 | | --- | --- | | 本次解质押股数 | 15,090,544 股 | | 占其所持股份比例 | 11.78% | | 占公司总股本比例 | 0.50% | | 解质押时间 | 2024 年 12 月 11 日 | | 持股数量 | 128,058,819 股 | | 持股比例 | 4.25% | | 剩余被质押股数 | 61,090,543 股 | | 剩余被质押股数占其所持有股份比例 | 47.71% | | 剩余被质押股数占公司总股本比例 | 2.03% | 一、本次股份解质押基本情况 乳源阳之光本次解 ...

Core Viewpoint - Dongyang Sunshine Pharmaceutical has submitted its listing application to the Hong Kong Stock Exchange, with CICC serving as the sole sponsor [1] Group 1: Company Overview - Established in 2003, Dongyang Sunshine Pharmaceutical is a comprehensive pharmaceutical company engaged in drug research and development, production, and commercialization [1] - The company focuses on innovative drugs, improved new drugs, generic drugs, and biosimilars, primarily targeting infection, chronic diseases, and tumors [1] - Dongyang Sunshine has a leading R&D platform, international standard production facilities, and a global sales network [1] Group 2: Research and Development - As of June 30, 2024, the company has 147 approved drugs globally and over 100 drugs in development, including 45 first-class innovative drugs [1] - Dongyang Sunshine is one of the few Chinese pharmaceutical companies that have successfully launched a first-class innovative drug through independent R&D and has three first-class innovative drugs under application for listing [1] Group 3: Market Performance - The company has shown strong performance in the anti-infection drug sector, with its product Kewi R (Oseltamivir Phosphate) capturing 64.8% of the Oseltamivir market in China in 2023 [1] - Dongyang Sunshine possesses a vast sales network covering China, Europe, and North America [1]

证券代码：600673 证券简称：东阳光 编号：临 2024-78 号 广东东阳光科技控股股份有限公司 二、回购股份的进展情况 关于调整回购股份方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次调整回购方案的具体内容：将回购价格由"不超过人民币 9.10 元/ 股"调整为"不超过人民币 12.00 元/股"；将回购资金来源由"公司自有资 金"调整为"自有资金和专项贷款资金"。除上述调整外，回购股份方案的其 他内容未发生变化。 ● 本次调整回购股份方案已经公司第十二届董事会第六次会议审议通过， 无须提交股东大会审议。 ● 本次股票回购专项贷款额度不代表公司对回购金额的承诺，具体回购股 份的金额以回购期满时实际回购的金额为准。 一、回购股份的基本情况 公司于 2024 年 7 月 25 日召开公司第十二届董事会第二次会议，审议通过 了《关于以集中竞价方式回购股份方案的议案》，同意公司以自有资金通过集 中竞价交易方式回购公司股份，回购价格不超过 9.10 元/股，回购金额为不低 于人民币 2 亿元且 ...

Company and Industry Summary Company Overview - The company operates in multiple segments, including electronic components, chemical new materials, and energy materials, with a focus on vertical integration across its supply chains [2][3][4] Key Business Segments 1. **Electronic Components** - This segment includes aluminum electrolytic capacitors and upstream materials such as electrode foil and aluminum foil [2][3] - The demand for aluminum electrolytic capacitors is driven by growth in the electronics industry, particularly in consumer electronics, 5G, and new energy vehicles [9] - The company has a production capacity of approximately 30 billion for aluminum electrolytic capacitors, which is a core asset [11] 2. **Chemical New Materials** - This includes refrigerants and PVDF (polyvinylidene fluoride) [3][4] - The company is expanding its production capabilities in this area, with a focus on high-end products in collaboration with partners [13] 3. **Energy Materials** - This segment focuses on materials related to lithium batteries and coal mining [3][4] - The company has established partnerships to enhance its supply chain from raw materials to end products [14] Market Dynamics - The company anticipates improvements in the capacitor and refrigerant industries in 2024, following a challenging 2023 [1] - The pricing for refrigerants has shown significant increases, with export prices nearing domestic prices, which is expected to enhance profitability [12] - The overall market for aluminum electrolytic capacitors is projected to grow, with domestic companies like the company competing against established Japanese firms [9] Financial Performance - Historical stock performance indicates significant growth phases, particularly from 2006 to 2007 and 2009 to 2011, driven by industry recovery and increased demand [6][7] - The company is expected to see a notable increase in profits in 2024, with estimates suggesting contributions exceeding 1 billion from various segments [16] Management and Strategy - The company is led by a family-controlled management team, with a strong emphasis on R&D capabilities [8][16] - The strategy involves vertical integration, allowing the company to control costs and enhance product offerings across its supply chains [5][19] Risks and Considerations - There are concerns regarding potential competition between the company's upstream and downstream operations, particularly in the capacitor market [18][19] - The company is navigating a cyclical industry landscape, with fluctuations in demand and pricing impacting overall performance [13][20] Conclusion - The company is positioned for growth in 2024, with strong fundamentals across its business segments and a focus on innovation and market expansion [17][21]

证券代码：600673 证券简称：东阳光 编号：临 2024-77 号 广东东阳光科技控股股份有限公司 重要内容提示: 关于控股股东及其一致行动人部分股份解质押及质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 控股股东深圳市东阳光实业发展有限公司（以下简称"深圳东阳光实业"） 持有本公司股份 582,469,389 股，占公司总股本的 19.33%；截至本次股份质押完 成后，深圳东阳光实业持有本公司股份累计质押数量 569,798,054 股，占其持股 数量的 97.82%。 控股股东之一致行动人宜昌东阳光药业股份有限公司（以下简称"宜昌 药业股份"）持有本公司股份 545,023,350 股，占公司总股本的 18.08%；截至本 次股份解质押及质押完成后，宜昌药业股份持有本公司股份累计质押数量 495,000,000 股，占其持股数量的 90.82%。 截至本公告披露日，公司控股股东累计质押股数数量为 569,798,054 股， 占其持股数量的 97.82%；控股股东及其一致行动人累计质押股数数量为 1,205 ...

证券代码：600673 证券简称：东阳光 公告编号：临 2024-76 号 广东东阳光科技控股股份有限公司 关于以集中竞价交易方式回购股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广东东阳光科技控股股份有限公司（以下简称"公司"）于 2024 年 7 月 25 日 召开公司第十二届董事会第二次会议，审议通过了《关于以集中竞价方式回购股份 方案的议案》，同意公司以自有资金通过集中竞价交易方式回购公司股份，回购价 格不超过 9.10 元/股，回购金额为不低于人民币 2 亿元且不超过人民币 4 亿元， 回购期限为自董事会审议通过本次回购股份方案之日起 6 个月内，详情请见公司 于 2024 年 7 月 26 日在上海证券交易所网站 www.sse.com.cn 上发布的《东阳光关 于以集中竞价交易方式回购股份的回购报告书》（临 2024-50 号）。 二、回购股份的进展情况 2024 年 11 月，公司未实施回购。 截至 2024 年 11 月月底，公司已累计回购股份 8,358,384 股，占公司总股本 的比例为 ...

重要内容提示: 证券代码：600673 证券简称：东阳光 编号：临 2024-75 号 广东东阳光科技控股股份有限公司 关于控股股东部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 控股股东深圳市东阳光实业发展有限公司（以下简称"深圳东阳光实业"） 持有本公司股份 582,469,389 股，占公司总股本的 19.33%；截至本次股份质押完 成后，深圳东阳光实业持有本公司股份累计质押数量 519,798,054 股，占其持股 数量的 89.24%。 截至本公告披露日，公司控股股东累计质押股数数量为 519,798,054 股， 占其持股数量比例为 89.24%；控股股东及其一致行动人累计质押股数数量为 1,205,979,141 股，占合计持股数量比例为 77.66%。 一、上市公司股份质押 广东东阳光科技控股股份有限公司（以下简称"公司"）于近日收到控股股 东深圳东阳光实业的通知，获悉其将其持有的公司部分无限售流通股进行了质押， 具体事项如下： | 股东名称 | 是否 为控 | 本次质押股数 | 是否 | ...

证券代码：600673 证券简称：东阳光 编号：临 2024-74 号 广东东阳光科技控股股份有限公司 关于控股股东之一致行动人部分股份解质押及质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 控股股东之一致行动人宜昌东阳光药业股份有限公司（以下简称"宜昌 药业股份"）持有本公司股份 545,023,350 股，占公司总股本的 18.08%；截至本 次股份解质押及质押完成后，宜昌药业股份持有本公司股份累计质押数量 545,000,000 股，占其持股数量的 99.99%。 截至本公告披露日，公司控股股东深圳市东阳光实业发展有限公司（以 下简称"深圳东阳光实业"）累计质押股数数量为 499,798,054 股，占其持股数量 的 86.68%；控股股东及其一致行动人累计质押股数数量为 1,185,979,141 股，占 合计持股数量比例为 76.66%。 一、 本次股份解质押及质押基本情况 广东东阳光科技控股股份有限公司（以下简称"公司"）于近日收到控股股 东之一致行动人宜昌药业股份的通知，获悉其将其持有 ...

证券代码：600673 证券简称：东阳光 编号：临 2024-73 号 广东东阳光科技控股股份有限公司 关于控股股东之一致行动人部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、 股东累计质押股份情况 截至本公告披露日，深圳东阳光实业及其一致行动人累计质押股份情况如下： | | | 持股比 | 本次质押前 | 本次质押后 | 占其所 | 占公司 | 已质押 | 已质押股份情况 已质押 | 未质押股份情况 未质押 | 未质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 持股数量 | | | | 持股份 | | | | | 股份中 | | 股东名称 | | 例 | 累计质押数 | 累计质押数 | | 总股本 | 股份中 | 股份中 | 股份中 | | | | （股） | （%） | 量（股） | 量（股） | 比例 | 比例 | 限售股 | 冻结股 | 限售股 | 冻结股 | | | | | | | （%） ...

Investment Rating - The report gives a "Buy" rating for the company [5][6][157]. Core Views - The company is positioned as a leader in the chemical materials and aluminum foil sectors, with a strong focus on refrigerants and aluminum foil products. It has a complete industrial chain from upstream raw materials to downstream applications, which enhances its competitive advantage [2][25][40]. - The refrigerant market is experiencing a fundamental shift in supply and demand dynamics, leading to a new period of product prosperity and performance improvement for the company [3][49][64]. - The company has a robust cash position, allowing it to return value to shareholders through significant cash dividends, reflecting its commitment to small investors [4][44]. Summary by Sections 1. Core Business Focus - The company has concentrated its operations on chemical and electronic new materials, having divested from its pharmaceutical business to enhance long-term competitiveness [25][27]. - It is a leading player in the refrigerant industry, with a well-established presence in the production of three generations of refrigerants and a forward-looking layout for the fourth generation [2][25]. 2. Refrigerant Market Dynamics - The company benefits from a favorable supply-demand balance in the refrigerant market, with significant price increases observed in key products like R125, R32, and R134a [3][61]. - The total refrigerant quota for the company has been adjusted upwards to 57,300 tons, positioning it among the top producers in China [68]. 3. Aluminum Foil and Capacitor Business - The company has a comprehensive aluminum foil production capability, including electrode foil and capacitor products, which are critical for various applications [4][104]. - The transition of high-energy-consuming processes to regions with lower electricity costs, such as Inner Mongolia, is expected to significantly reduce production costs [141][144]. 4. Financial Performance and Forecast - The company is projected to achieve revenues of 133.5 billion, 160.2 billion, and 200.3 billion yuan for the years 2024, 2025, and 2026, respectively, with corresponding net profits of 5.0 billion, 11.9 billion, and 16.8 billion yuan [5][153]. - The expected improvement in profitability is driven by rising prices in the refrigerant market and cost savings from operational efficiencies [151][153]. 5. Investment Recommendation - Given the company's strong market position, expected growth in key product lines, and favorable financial metrics, it is recommended as a buy with a potential for significant returns [5][157].